| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Updated 2025 Guidance
Mirion is revising its Organic Revenue growth guidance for the fiscal year ending December 31, 2025. This does not include the impact of Paragon to our consolidated financial results.
Organic Revenue growth for the year ending December 31, 2025 compared to the year ended December 31, 2024 is now expected to be approximately 4.5% – 6.0% (previously 5.0% – 7.0%), reflecting (1) reduced Labs & Research end-market expectations; (2) reduced China-related demand not associated with nuclear power demand; and (3) delayed timing of an expected defense dosimetry order in Europe.
Posted In: MIR
